medigraphic.com
ISSN 0187-5337 (Impreso)
Instituto Nacional de Perinatología

2006, Número 4

<< Anterior Siguiente >>

Perinatol Reprod Hum 2006; 20 (4)


Anticonceptivos orales combinados y enfermedad cardiovascular

Garza-Flores J, Sierra-Ramírez JA

Idioma: Español
Referencias bibliográficas: 54
Paginas: 98-111
Archivo PDF: 149.80 Kb.


RESUMEN

Alrededor del mundo existen más de 120 millones de mujeres que emplean algún tipo de anticonceptivo hormonal oral. Si bien la disminución en la dosis de los anticonceptivos orales combinados, particularmente en el contenido total de estrógenos, ha hecho que esta opción anticonceptiva, una de las más atractivas en la regulación de la fertilidad. Las usuarias, en su mayoría mujeres sanas con una baja incidencia general de enfermedades importantes, requieren de información veraz y actualizada acerca de los riesgos cardiovasculares que conllevan el empleo de estos métodos anticonceptivos.
En este trabajo de revisión, se examinan estudios epidemiológicos sobre la relación entre las enfermedades cardiovasculares y el empleo de anticonceptivos hormonales orales. Específicamente, se analiza los factores de riesgo para el desarrollo de infarto agudo del miocardio, accidentes cerebrovasculares, isquémicos y hemorrágicos, así como tromboembolismo venoso.
Se recomienda que antes de prescribir anticonceptivos hormonales orales a mujeres en edad reproductiva, se haga un análisis individual y profundo de los factores de riesgo asociados con su empleo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Borgelt-Hansen L. Oral contraceptives: An up date of health benefits and risks. J Am Pharm Assoc 2001; 41: 875-86.

  2. Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction 2006; 12: 169-78.

  3. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas 2003; 46S1: S7-S16.

  4. Garza FJ, Martínez MDL, Pérez PG. Anticoncepción hormonal: reevaluación de sus riesgos y beneficios. En: López G, Ayunes J, Solis JA, Omran AR. Salud reproductiva en las Américas. Ed. Organización Panamericana de la Salud; 1992, p. 226-55.

  5. Pérez-Palacios, Larrea F, Pérez AE, Chavez BA, Vilchis F, García GA, Garza-Flores J. Significado biológico del metabolismo de progestinas sintéticas. En: Pérez-Palacios G, Garza-Flores J y Hall (eds.) Avances recientes en regulación de la fertilidad. Vol. 1. Ed. México, D.F. Piensa; 1987.

  6. Programa Especial de Investigaciones, Desarrollo y Formación de Investigadores sobre Reproducción Humana. Guidelines for the toxicological and clinical assessment and post-registration surveillance of steroidal contraceptive drugs. Ginebra, Organización Mundial de la Salud. WHO/HRP/SP. REP/87.1.1987.

  7. Lewis MA, Spitzer WO, MacRae KD. Third generation oral contraceptives. Brith Med J 1996; 312: 577-8.

  8. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case control studies. I. Principles. Am J Epidemiol 1992; 135: 1019-28.

  9. Inman WH, Vessey MP, Westerholm B, Engelund A. Thomboembolic disease end the steroidal content of oral contraceptives. A report of the Committee on Safety of Drugs. Brith Med J 1970; 2: 203-9.

  10. Organización Mundial de la Salud, Enfermedades Cardiovasculares y Contracepción con Hormonas Esteroides. Informe Técnico 877. Ginebra, Suiza, 1998.

  11. Davies MJ. The pathophysiology of ischaemic heart disease. In: Weatherall DJ, Ledingham, Warell DA (Eds.). Oxford’s Textbook of medicine. New York; Oxford University Press; 1996; 2318-21.

  12. Khaw KT. Epidemiology of coronary heart disease in women. In: Julian JD, Wenger NK. Eds. Women and heart disease. London: Martin Dunitz; 1997, p. 7-20.

  13. Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and Conovid. Lancet, i: 111, 1963.

  14. Mann JI, Vessey MP, Thorogood M, Doll SR. Myocardial infarction in young women with special reference to oral contraceptive practice. Brith Med J 1975; 2: 241-5.

  15. Mann JI, Thorogood M, Waters WE, Powell C. Oral contraceptives and myocardial infraction in young women: a further report. Brith Med J 1975; 3: 631-2.

  16. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978; 240: 2548-52.

  17. Mant D, Villard-Mackintosh L, Vessey MP, Yeates D. Myocardial infarction and angina pectoris in young women. J Epidemiol Comm Health 1987; 41: 215-9.

  18. Stampfer MJ, Willet WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med 1988; 319: 1313-7.

  19. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women. Evidence from the Royal College of Practitioner’s Oral Contraception Study. Brith Med J 1989; 298: 165-8.

  20. Rosemberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990; 131: 1009-16.

  21. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptives use still associated with an increased risk of fatal myocardial infarction? Report of a case control study. Brith J Obst Gynecol 1991; 98: 1245-53.

  22. D’Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health 1994; 48324-5.

  23. Sidney S, Petitti DB, Quesenberry CP Jr, Klatsky AL, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996; 88: 939-44.

  24. OMS. Enfermedades Cardiovasculares y Contracepción con Hormonas Esteroides. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-9.

  25. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129-40.

  26. Collaborative study of stroke in young women. Oral contraception and increased risk of cerebral ischemia or thrombosis. N Eng J Med 1973; 288: 871-8.

  27. Vessey MP, Lawless M, Yeates D. Oral contraceptives and stroke: findings in a large prospective study. Brith Med J 1984; 289: 530-1.

  28. Thorogood M, Mann J, Murphy M, Vessey M. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol 1992; 136: 35-45.

  29. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners’ oral contraception study. Stroke 1994; 25: 935-42.

  30. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335: 8-15.

  31. OMS. Estudio de la OMS en colaboración sobre enfermedades cardiovasculares y contracepción con hormonas esteroides. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results from and international, multicentre, case-control study. Lancet 1996; 348: 505-10.

  32. Schwartz SM, Siscovick DS, Longstreth WT Jr, Psaty BM, Beverly RK, Raghunathan TE, Lin D, Koepsell TD. Use of low-dose contraceptives and stroke in young women. Ann Intern Med 1997; 127: 596-603.

  33. Vessey MP, Doll R. Investigation of relation between oral contraceptives and thromboembolic disease. A further report. Brith Med J 1969; 2: 651-7.

  34. Startwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J of Epidemiol 1969; 90: 365-80.

  35. Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol 1979; 110: 188-95.

  36. Inman WHW, Vessey MP. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of childbearing age. Brit Med J 1968; 2: 193-9.

  37. Royal College of General Practitioners. Oral Contraception Study. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978; 28: 393-9.

  38. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thromboembolism in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.

  39. Okrainc K, Banerjee DK, Eisenber JM. Coronary artery disease in the developing world. Am Heart J 2004; 148: 7-15.

  40. Kannel WB, D’Agostino RB, Sullivan L, Wilson PWF. Concept and usefulness of cardiovascular risk profiles. Am Heart J 2004; 148: 16-26.

  41. Zhu W, Everson WV, Smart EJ. Estrogen in cardiovascular disease. Curr Opin Lipidol 2004; 15: 589-93.

  42. Kirschstein R. Menopausal Hormone Therapy: Summary of a Scientific Workshop. Ann Intern Med 2003; 138: 361-4.

  43. Neves-e-Castro M. Menopause in crisis post-Women’s Health initiative? A view based on personal clinic experience. Human Reprod 2003; 18: 2512-8.

  44. Ramirez PM, Haas S. Hormone replacement therapy for women: the benefits, risks, and considerations for use in 2003. Curr Opin Endocrinol Diabetes 2003; 10: 400-18.

  45. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovascular Research 2002; 53: 550-7.

  46. Porter JB Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985; 66: 1-4.

  47. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Brith Med J 1986; 292: 526.

  48. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987; 69: 91-5.

  49. Estudio de la OMS en colaboración. Cardiovascular disease and use of oral contraceptives. Bull of World Health Organization 1989; 67: 417-23.

  50. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52.

  51. Vandenbroucke JP. Increased risk of venous thromboembolism in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.

  52. Farmen RDT, Preston TD. The risk of venous thromboembolism associated with low-oestrogen oral contraceptives. Obstet Gynecol 1995; 15: 195-200.

  53. Estudio de la OMS en colaboración sobre enfermedades cardiovasculares y contracepción con hormonas esteroides. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.

  54. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third-generation progestagens: role of bias in observational research. Contraception 1996; 54: 5-13.




2020     |     www.medigraphic.com